Mirae Asset Global Investments Co. Ltd. Buys 1,367 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)

Mirae Asset Global Investments Co. Ltd. grew its stake in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) by 9.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 15,951 shares of the company’s stock after purchasing an additional 1,367 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Olema Pharmaceuticals were worth $224,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of OLMA. Public Employees Retirement System of Ohio bought a new position in shares of Olema Pharmaceuticals in the third quarter valued at approximately $35,000. China Universal Asset Management Co. Ltd. bought a new position in shares of Olema Pharmaceuticals in the fourth quarter valued at approximately $89,000. SG Americas Securities LLC bought a new position in shares of Olema Pharmaceuticals in the third quarter valued at approximately $142,000. Raymond James Financial Services Advisors Inc. bought a new position in shares of Olema Pharmaceuticals in the third quarter valued at approximately $164,000. Finally, Caxton Associates LP bought a new position in shares of Olema Pharmaceuticals in the third quarter valued at approximately $166,000. Institutional investors own 91.78% of the company’s stock.

Analyst Ratings Changes

OLMA has been the topic of a number of recent analyst reports. Citigroup initiated coverage on Olema Pharmaceuticals in a report on Tuesday, January 30th. They set a “buy” rating and a $20.00 price target on the stock. Capital One Financial reiterated an “overweight” rating on shares of Olema Pharmaceuticals in a report on Thursday, February 22nd. Finally, The Goldman Sachs Group initiated coverage on Olema Pharmaceuticals in a report on Tuesday, April 2nd. They set a “buy” rating and a $24.00 price target on the stock. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $21.43.

Insider Buying and Selling at Olema Pharmaceuticals

In other Olema Pharmaceuticals news, Director Cyrus Harmon sold 25,000 shares of the business’s stock in a transaction on Wednesday, January 31st. The stock was sold at an average price of $12.23, for a total value of $305,750.00. Following the sale, the director now directly owns 876,283 shares in the company, valued at $10,716,941.09. The sale was disclosed in a filing with the SEC, which is accessible through this link. Insiders have sold a total of 70,000 shares of company stock worth $835,400 over the last ninety days. 23.50% of the stock is currently owned by company insiders.

Olema Pharmaceuticals Price Performance

Shares of OLMA opened at $9.95 on Friday. The firm has a market cap of $556.40 million, a PE ratio of -4.61 and a beta of 2.10. The stock’s fifty day moving average price is $11.86 and its two-hundred day moving average price is $12.87. Olema Pharmaceuticals, Inc. has a 1 year low of $4.26 and a 1 year high of $17.79.

Olema Pharmaceuticals (NASDAQ:OLMA) last issued its earnings results on Monday, March 11th. The company reported ($0.49) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.49). Sell-side analysts anticipate that Olema Pharmaceuticals, Inc. will post -2.34 earnings per share for the current fiscal year.

Olema Pharmaceuticals Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.